Milestone Pharmaceuticals Files 8-K Report
Ticker: MIST · Form: 8-K · Filed: May 13, 2024 · CIK: 1408443
Sentiment: neutral
Topics: 8-K, financial-results, operations
TL;DR
Milestone Pharma dropped an 8-K on May 13th - check financials and operations.
AI Summary
On May 13, 2024, Milestone Pharmaceuticals Inc. filed an 8-K report detailing its financial results and operations. The company, incorporated in Quebec, operates in the pharmaceutical preparations sector and is headquartered in Montreal. This filing serves as a current report under the Securities Exchange Act of 1934.
Why It Matters
This 8-K filing provides essential updates on Milestone Pharmaceuticals' financial condition and operational status, which are crucial for investors to assess the company's performance and future prospects.
Risk Assessment
Risk Level: low — This filing is a standard 8-K report for financial results and operations, not indicating any immediate or unusual risks.
Key Players & Entities
- Milestone Pharmaceuticals Inc. (company) — Registrant
- May 13, 2024 (date) — Date of earliest event reported
- Montreal (location) — Principal executive offices city
- Quebec (location) — State of incorporation
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Milestone Pharmaceuticals Inc.'s Results of Operations and Financial Condition, as well as Financial Statements and Exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on May 13, 2024.
Where is Milestone Pharmaceuticals Inc. headquartered?
Milestone Pharmaceuticals Inc.'s principal executive offices are located in Montreal, Quebec.
What is Milestone Pharmaceuticals Inc.'s Standard Industrial Classification code?
Milestone Pharmaceuticals Inc.'s Standard Industrial Classification code is 2834, which corresponds to Pharmaceutical Preparations.
Under which section of the Securities Exchange Act is this report filed?
This report is filed as a Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 451 words · 2 min read · ~2 pages · Grade level 9.9 · Accepted 2024-05-13 07:34:07
Filing Documents
- tm2414191d1_8k.htm (8-K) — 27KB
- tm2414191d1_ex99-1.htm (EX-99.1) — 64KB
- tm2414191d1_ex99-1img001.jpg (GRAPHIC) — 20KB
- 0001104659-24-060221.txt ( ) — 302KB
- mist-20240513.xsd (EX-101.SCH) — 3KB
- mist-20240513_lab.xml (EX-101.LAB) — 33KB
- mist-20240513_pre.xml (EX-101.PRE) — 22KB
- tm2414191d1_8k_htm.xml (XML) — 4KB
02
Item 2.02. Results of Operations and Financial Condition. On May 13, 2024, Milestone Pharmaceuticals Inc. (the "Company") issued a press release announcing its financial results for the first quarter ended March 31, 2024, which also provided a clinical and corporate update. A copy of the press release is attached as Exhibit 99.1 hereto and is incorporated herein by reference.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release dated May 13, 2024 104 Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MILESTONE PHARMACEUTICALS INC. By: /s/Amit Hasija Amit Hasija Chief Financial Officer Dated: May 13, 2024